- Home
- STRO vs CUE Comparison
STRO vs CUE Comparison
Compare STRO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- CUE
- Stock Information
- Founded
- STRO 2003
- CUE 2014
- Country
- STRO United States
- CUE United States
- Employees
- STRO N/A
- CUE N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- CUE Health Care
- Exchange
- STRO Nasdaq
- CUE Nasdaq
- Market Cap
- STRO 69.1M
- CUE 59.5M
- IPO Year
- STRO 2018
- CUE 2018
- Fundamental
- Price
- STRO $0.97
- CUE $0.77
- Analyst Decision
- STRO Hold
- CUE Strong Buy
- Analyst Count
- STRO 7
- CUE 2
- Target Price
- STRO $1.97
- CUE $3.00
- AVG Volume (30 Days)
- STRO 553.4K
- CUE 109.1K
- Earning Date
- STRO 08-07-2025
- CUE 08-12-2025
- Dividend Yield
- STRO N/A
- CUE N/A
- EPS Growth
- STRO N/A
- CUE N/A
- EPS
- STRO N/A
- CUE N/A
- Revenue
- STRO $104,473,000.00
- CUE $8,286,000.00
- Revenue This Year
- STRO $65.42
- CUE N/A
- Revenue Next Year
- STRO N/A
- CUE $10.19
- P/E Ratio
- STRO N/A
- CUE N/A
- Revenue Growth
- STRO N/A
- CUE N/A
- 52 Week Low
- STRO $0.52
- CUE $0.45
- 52 Week High
- STRO $4.80
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- STRO 58.41
- CUE 43.61
- Support Level
- STRO $0.90
- CUE $0.77
- Resistance Level
- STRO $1.18
- CUE $0.89
- Average True Range (ATR)
- STRO 0.09
- CUE 0.04
- MACD
- STRO 0.01
- CUE -0.01
- Stochastic Oscillator
- STRO 43.43
- CUE 4.84
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.